Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The Clinical Treatment Score post-5-years tool helps clinicians identify which patients are at high risk of their cancers recurring after completing five years of adjuvant hormone therapy.
